Is Bristol Myers Squibb's Deucravacitinib a Game-Changer for SLE Patients and BMY Investors

Related Articles

Why is Barclays Bullish on Bristol-Myers Squibb (BMY) Now

7 months ago

Is Bristol Myers Squibb's New Multiple Myeloma Drug a Game Changer

7 months ago

Why Are UnitedHealth Group and Bristol-Myers Squibb Attracting Hedge Funds

4 months ago

Why Are Barclays Analysts Bullish on Eli Lilly and Bristol-Myers Squibb

7 months ago

Category

You may also like

Stock News•2 weeks ago

Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus

Immunovant's IMVT-1402 missed statistical significance on the primary CLASI-A endpoint at Week 12 in cutaneous lupus erythematosus, prompting the company to halt development in CLE despite positive tr...

IMVT

Share

Stock News•3 weeks ago

Can Sotyktu's Long-Term PsA Data Boost Bristol Myers' Prospects?

Bristol Myers' Sotyktu showed durable psoriatic arthritis responses at two years, supporting its growth strategy as competition intensifies. The long-term data may bolster the drug's positioning in th...

BMY

Share

Stock News•2 months ago

Q32 Bio: Bempikibart's Progress Keeps Me Bullish

Q32 Bio's bempikibart showed meaningful hair regrowth in severe alopecia areata, including JAK-experienced patients, with durable benefits after treatment cessation. The safety profile could different...

QTTB

Share